Liposomal doxorubicin
Executive Summary
Pfizer licenses worldwide rights to The Liposome Company's TLC D-99, a liposomal formulation of doxorubicin, currently in Phase II. Pfizer, which will take over funding of the clinical program, says it expects to manufacture and market the product on a worldwide basis. Princeton-based Liposome said it will participate in Pfizer-controlled development committee and receive development milestone payments and product royalties.